Skip main navigation

Home > Search Results

Main contents starts here

Search Results

1 - 20 of about 264

Total 264 documents found.

  •  
  • Takeda Introduces ‘Cisco TelePresence’ (Advanced Videoconferencing System) September 10, 2009
  • Osaka, Japan, September 10, 2009 --- Takeda Pharmaceutical Company Limited (Head Office: Chuo-ku, Osaka; President: Yasuchika Hasegawa, “Takeda”) announced today that it has introduced Cisco TelePresence™, －an advanced videoconferencing system providing both high-resolution visuals and a high-quality audio environment. Cisco TelePresence™ was provided by Cisco Systems G.K. (Headquarters: Minato-ku, Tokyo; President & CEO: Edzard J.C. Overbeek, “Cisco”), and IBM Japan, Ltd. (Headquarters: Minato-ku, Tokyo; President: Takayuki Hashimoto; NYSE: IBM, “IBM Japan”) provided support to introduce this videoconfereincing system at Takeda. .
  • Terumo and Takeda to Co-promote Takeda’s Ethical Narcotic Formulations September 3, 2009
  • Tokyo and Osaka, Japan, September 3, 2009 - Terumo Corporation (Head Office: Shibuya-ku, Tokyo; President: Akira Takahashi, “Terumo”) and Takeda Pharmaceutical Company Limited (Head Office: Chuo-ku, Osaka; President: Yasuchika Hasegawa, “Takeda”) announced jointly today that the two companies will commence in coming October the co-promotion of ethical narcotic formulations that Takeda is manufacturing and marketing in Japan.
  • Agreements Concluded for “SELTOUCH ® Pap 70, 140”Transdermal Absorption-type Analgesic and Anti-inflammatory Agent July 27, 2009
  • Wyeth K.K. (Headquarters: Shinagawa-ku, Tokyo, President & Representative Director Michael Goettler, “WKK”), ASKA Pharmaceutical Co., Ltd (Headquarters: Minato-ku, Tokyo, President, Representative Director Takashi Yamaguchi, “ASKA”) and Takeda Pharmaceutical Company Limited (Headquarters: Chuo-ku, Osaka, President & CEO Yasuchika Hasegawa, “Takeda”) today announced changes to the Japanese distribution, sales and promotion for WKK’s transdermal absorption-type analgesic and anti-inflammatory agent, “SELTOUCH ® Pap 70, 140” (“SELTOUCH”). WKK and ASKA signed an agreement in which the sales right for SELTOUCH is granted to ASKA. ASKA and Takeda also signed an agreement in which the sales and promotion of SELTOUCH are entrusted to Takeda.
  • Takeda to Create Global Centers of Excellence
    Reorganization helps Takeda realize globalization vision March 31, 2009
  • Osaka, Japan, March 31, 2009 -Takeda Pharmaceutical Company Limited ("Takeda") today announced a reorganization of its corporate structure, as part of its 2006-2010 Medium-Term Plan vision to become a global pharmaceutical company with highly integrated global operations. In order to become more responsive to rapid changes in the global operating environment and to maximize the global market potential of new products and the company’s global presence, the company is streamlining executive reporting relationships to Yasuchika Hasegawa, President, by creating corporate-level, center of excellence R&D, commercial and administrative functions. Effective April 1, 2009, Shigenori Ohkawa, Ph.D., will become Chief Scientific Officer (CSO), and Alan MacKenzie will become Executive Vice President (EVP) International Operations. Additionally, a Chief Administrative Officer (CAO) role will be established.
  • Approval of an Additional Indication of Combination Therapy of Glufast and Insulin Sensitizer in Japan February 24, 2009
  • Matsumoto, Japan & Osaka, Japan, February 24, 2009 --- Kissei Pharmaceutical Co., Ltd (President, C.E.O. Mutsuo Kanzawa, “Kissei”) and Takeda Pharmaceutical Company Limited (President, Yasuchika Hasegawa, “Takeda”) announced today that an additional indication of “combination therapy with insulin sensitizer” for Glufast (geneic name: mitiglinide) 5mg tablet and 10mg tablet, which is being co-marketed by Kissei and Takeda, was approved by the regulatory authorities in Japan.
  • ULORIC® (TMX-67, febuxostat) Receives FDA Approval forthe Chronic Management of Hyperuricemia in Patients with Gout February 14, 2009
  • Tokyo and Osaka, Japan, February 14, 2009 – Teijin Pharma Limited (Head office: Chiyoda-ku, Tokyo; President: Osamu Nishikawa, hereafter “Teijin Pharma”) and Takeda Pharmaceutical Company Limited (Head office: Chuo-ku, Osaka; President: Yasuchika Hasegawa, hereafter “Takeda”) announced today that on February 13, 2009, Teijin Pharma’s U.S. licensee for febuxostat and Takeda’s wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., (Head office: Deerfield, Illinois) received FDA marketing approval for ULORIC (febuxostat) for the chronic management of hyperuricemia in patients with gout. Takeda Pharmaceuticals North America is the sole developer and marketer of the product, ULORIC in the U.S.
  • AMITIZA™(lubiprostone), the First Selective Chloride Channel Activator for the Treatment of Chronic Idiopathic Constipation, Launches in the United States
    Novel mechanism of action provides effective and predictable relieffor adults living with chronic idiopathic constipation April 26, 2006
  • Bethesda, Md., and Lincolnshire, Il., April 25, 2006- Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc., announced today that AMITIZA™ (lubiprostone), 24-mcg soft-gel capsules, approved by the U.S. Food and Drug Administ-ration (FDA) in January 2006, is now available by prescription in pharmacies across the United States for the treatment of chronic idiopathic constipation in adults. AMITIZA (pronounced ahm-e-TEASE-a) is the first selective chloride channel activator approved for therapeutic use in chronic idiopathic constipation, a condition that affects both men and women and affects patients over the age of 65 more frequently."AMITIZA is an important new option for people living with chronic idiopathic constipation who may be unsatisfied with traditional treatment options, including lifestyle and dietary changes, laxatives and stool softeners," said Sachiko Kuno, Ph.D., co-founder, president and chief executive officer of Sucampo. "As a science-driven pharmaceutical company, Sucampo is pleased to work with Takeda Pharmaceuti-cals North America to make this innovative new therapeutic option available to physicians and patients in the United States."AMITIZA works by increasing fluid secretion locally in the small intestine by activating the ClC-2 chloride channel, and thereby increasing the passage of the stool and improving symptoms associated with chronic idiopathic constipation. In clinical trials, 60 percent of patients who used AMITIZA experienced a spontaneous bowel movement within the first 24 hours. AMITIZA improved signs and symptoms related to chronic constipation, including abdominal bloating, discomfort, stool consistency and straining. Additionally, these symptomatic improvements lasted over the six to 12 month treatment period. "The availability of AMITIZA™ is exciting news for the millions of Americans who suffer from chronic idiopathic constipation and deal with its daily conse-quences," said John Johanson, M.D., clinical associate professor, University of Illinois College of Medicine. "Unlike many treatments that may fail to control symptoms adequately or lose effectiveness with time, AMITIZA provides fast and predictable relief of chronic idiopathic constipation."AMITIZA is developed by Sucampo Pharmaceuticals, Inc., and will be jointly marketed in the United States by Sucampo Pharmaceuticals, Inc., and Takeda Pharma-ceuticals North America, Inc. The AMITIZA sales force in the United States will comprise representatives from both companies."Takeda looks forward to working with Sucampo to successfully launch AMITIZA and help make it a trusted and valuable therapy for the treatment of chronic idiopathic constipation," said Art Rice, general manager, Gastroenterology. "AMITIZA has been shown to deliver targeted and predictable relief to people with chronic idiopathic constipation, and we believe that through its novel mechanism of action, this drug may help fill an important therapeutic gap for many patients."
  • Transfer of Shares of Mitsui Takeda Chemicals, Inc. from Takeda to Mitsui Chemicals April 3, 2006
  • Osaka, Japan, --- Takeda Pharmaceutical Company Limited ("Takeda", President & COO : Yasuchika Hasegawa) announced today that all of Takeda's shares of Mitsui Takeda Chemicals Inc. ("MTCI", President: Masafumi Kataita) had been transferred to Mitsui Chemicals, Inc. ("MCI", President: Kenji Fujiyoshi) on April 1. Upon transfer of shares, MTCI changed its name to Mitsui Chemicals Polyurethanes, Inc.
  • Takeda Submits New Drug Application for Extended Release Type 2 Diabetes Medication, ACTOplus met™(pioglitazone HCl and metformin HCl) April 3, 2006
  • LINCOLNSHIRE, Ill, April 3, 2006 - Takeda Global Research & Development Center (TGR&D) today announced that the company has submitted a New Drug Application (NDA) for an extended release version of the combination medication ACTOplus met™ (pioglitazone HCl and metformin HCl) to the United States Food and Drug Administration (FDA) for the treatment of type 2 diabetes. This new formulation (ACTOplus met™ XR) would allow for once−daily dosing, while ACTOplus met™ (immediate release) is already available being marketed by Takeda Pharmaceuticals North America, Inc. ACTOplus met is an oral medication that combines ACTOS, which directly targets insulin resistance - a condition in which the body does not efficiently use the insulin it produces - with metformin, which acts primarily by reducing the amount of glucose produced by the liver. These medications work in combination to help patients with type 2 diabetes manage their blood glucose levels. The NDA submission represents yet another milestone for Takeda, following the NDA approvals of ROZEREM™ (ramelteon). "We are certainly proud of this NDA submission, and the ACTOS portfolio of products," said John Yates, M.D., president of TGR&D. "Not all patients are alike, especially in diabetes, and the addition of this new product would provide patients and their physicians with more options and greater flexibility, while continuing to provide the benefits of treatment with ACTOS."Extended-release metformin, one of the active ingredients in ACTOplus met XR, was developed by Andrx Corporation. Takeda Pharmaceutical Company Limited, signed an agreement with Andrx Corporation covering extended release metformin in December 2003.
  • Transfer of Shares of BASF Takeda Vitamin K.K. from Takeda to BASF Japan January 5, 2006
  • OSAKA, JAPAN --- Takeda Pharmaceutical Company Limited ("Takeda", President & COO: Yasuchika Hasegawa) announced today that all of Takeda's shares of BASF Takeda Vitamin K.K. ("BTV", President: Akihiko Sato) were transferred to BASF Japan Ltd. ("BASF Japan", President: Tomoyoshi Naruo) on January 4, 2006, based on the original joint venture agreement between BASF Japan and Takeda concluded in January 2001.
  • ACTOplus met™ (pioglitazone HCl and metformin HCl) Now Available in U.S. Pharmacies
    New product combines two widely used diabetes medications in a single tablet, offering patients a convenient option November 1, 2005
  • LINCOLNSHIRE, Ill., November 1, 2005 −Takeda Pharmaceuticals North America, Inc. today announced that ACTOplus met™(pioglitazone HCl and metformin HCl) is now available by prescription in pharmacies across the United States for the treatment of type 2 diabetes. This is the second Takeda product launch in the United States this year, following the approval of ROZEREM™ (ramelteon) on July 22, 2005.ACTOplus met™ combines ACTOS®(pioglitazone HCl) and metformin, two widely used diabetes medications, in a single tablet. ACTOS directly targets insulin resistance, a condition where the body does not efficiently use the insulin it produces, and metformin acts primarily by reducing the amount of glucose produced by the liver. These medications work in combination to help patients with type 2 diabetes manage their blood glucose levels. "Takeda is pleased to provide ACTOplus met, an important addition to the ACTOS family of products," said Mark Booth, president of Takeda. "Since most people with type 2 diabetes take multiple therapies to reach their target glucose levels, we believe that this combination pill will offer an effective, convenient new treatment option for patients."To offer physicians greater flexibility in treating their patients' needs, ACTOplus met will be available in two dosages of pioglitazone/metformin − 15 mg/500 mg and 15 mg/850 mg − both of which are to be given once a day or in divided doses not exceeding the maximum recommended daily doses of pioglitazone 45 mg and metformin 2,550 mg, according to the approved labeling.According to the American Diabetes Association, diabetes affects more than 18 million people, and type 2 diabetes is the most common form of the disease. Both ACTOS and metformin are widely used medications in the treatment of type 2 diabetes and both have a known safety profile. Combining these medications may provide patients with an easier way to take the two drugs, as they are already often prescribed together to help manage the disease.
  • ROZEREM™ (ramelteon) Now Available in U.S. Pharmacies
    First and only non-scheduled prescription sleep medication September 26, 2005
  • LINCOLNSHIRE, Ill., September 26 − Takeda Pharmaceuticals North America, Inc. today announced that ROZEREM™(ramelteon) 8-mg tablets are now available by prescription in pharmacies across the U.S. for the treatment of insomnia characterized by difficulty with sleep onset. ROZEREM is the first prescription insomnia medication with a new therapeutic mechanism of action in 35 years, and can be prescribed for long-term use in adults.ROZEREM is the first and only prescription sleep medication that has shown no evidence of abuse and dependence in clinical studies. As a result, ROZEREM is not designated as a controlled substance by the U.S. Drug Enforcement Administration (DEA). With the exception of ROZEREM, all other prescription medications indicated for insomnia are classified as controlled substances by the DEA, most as Schedule IV drugs."The availability of ROZEREM represents the second Takeda-discovered-and-developed product to reach physicians and patients in our brief history," said Mark Booth, president of Takeda Pharmaceuticals North America. "We are excited to be able to offer an important new option for people living with insomnia that has not shown the potential for abuse or dependence."ROZEREM has a unique therapeutic mechanism of action that selectively targets two receptors located in the brain's suprachiasmatic nucleus (SCN). The SCN is known as the body's "master clock" because it regulates 24-hour, or circadian, rhythms including the sleep-wake cycle.
  • Transfer of Shares of Takeda Schering-Plough Animal Health K.K. from Takeda to Schering-Plough June 28, 2005
  • OSAKA, JAPAN --- Schering-Plough K.K. ("SPKK", President: Masao Torii) and Takeda Pharmaceutical Company Limited ("Takeda", President & COO: Yasuchika Hasegawa) announced today that all of Takeda's shares of Takeda Schering-Plough Animal Health K.K. ("TSA", President and Representative Director: Leopoldo Nanni) will be transferred to Schering-Plough ("SP") as of end of June 2005, based on the agreement concluded in March 2000.
  • Partial Transfer of Wyeth K.K. Equity from Takeda to Wyeth April 7, 2005
  • Madison N.J., U.S.A. and Osaka, Japan −−− Wyeth (Headquarters: Madison, N.J., U.S.A.; President, Chief Executive Officer and Chairman: Robert Essner, "Wyeth") and Takeda Pharmaceutical Company Limited (Headquarters:, Osaka; President:Yasuchika Hasegawa, "Takeda") agreed that Takeda, which holds a 40 percent share, would transfer a 10 percent share of Wyeth K.K. (Headquarters:, Tokyo; President: Rune Bremberg) to Wyeth with the transfer to be completed today.
  • Takeda to Transfer its Life-environmental Business to Osaka Gas March 30, 2005
  • OSAKA, JAPAN −−− Osaka Gas Co., Ltd. ("Osaka Gas", President: Hirofumi Shibano) and Takeda Pharmaceutical Company Limited ("Takeda", President: Yasuchika Hasegawa) jointly announced today the transfer of shares of Takeda's five subsidiaries and affiliates engaged in life-environmental business to Osaka Gas Chemicals Co., Ltd. ("Osaka Gas Chemicals", President: Mitsuo Endo), a subsidiary of Osaka Gas. Such five companies include Japan EnviroChemicals, Ltd. ("Japan EnviroChemicals" President: Atsuo Kobayashi), a wholly owned subsidiary of Takeda.
  • Takeda to Acquire Syrrx February 7, 2005
  • Takeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda", President and Chief Operating Officer: Yasuchika Hasegawa) announced today that Takeda and Syrrx Inc. (San Diego, CA, "Syrrx", Chairman of the Board: Samuel D.Colella) agreed on February 5, 2005 (PST) to merge Syrrx, Inc. into the Takeda Group. The merger is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and is subject to the satisfaction of other customary closing conditions. Upon successful completion of the transaction, which is anticipated to occur in the first quarter of 2005, Syrrx will become a subsidiary of Takeda America Holdings, Inc., a wholly owned subsidiary of Takeda.

Pages:[1] [2] [3] [4] [5] [6] [7] [8] [9] [10]   Next

Page Top